Jade Biosciences, Inc. (JBIO) Form 8-K — Jul 1, 2026
Jade Biosciences entered into a material definitive agreement with Paragon Therapeutics to obtain an exclusive worldwide license for monospecific antibodies targeting an undisclosed therapeutic target. The JADE301 License Agreement grants Jade the rights to develop, sell, and sublicense products across all therapeutic areas for human disease. Under the terms, Jade is obligated to pay Paragon up to $22.0 million in development and regulatory milestones. This includes a $2.5 million payment due upon the first dosing of a human patient in a Phase 1 trial, following a $1.5 million fee paid in January 2026.
Key figures
- Total dev milestones usd
- 22000000
- Sublicensing fees max usd
- 20100000
- Phase1 dosing milestone usd
- 2500000
- Candidate nomination fee usd
- 1500000
Price after filing
Close on the filing date to close N calendar days later (from $22.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.